FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is an isolated antibody or a binding fragment thereof capable of binding to influenza A virus hemagglutinin and neutralising at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus, which comprise HCDR1 with sequence SEQ ID NO: 113, HCDR2 with sequence SEQ ID NO:114, HCDR3 SEQ with sequence ID NO:115, LCDR1 with sequence SEQ ID NO:118, LCDR2 with sequence SEQ ID NO:119 and LCDR3 with sequence SEQ ID NO:120. Uses of said antibody are presented.
EFFECT: invention widens the range of agents that neutralise the influenza A virus.
24 cl, 15 dwg, 13 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
